|1.||Kirn, D: 12 articles (02/2007 - 03/2000)|
|2.||Nemunaitis, J: 6 articles (11/2007 - 08/2000)|
|3.||Randlev, B: 6 articles (03/2005 - 08/2000)|
|4.||Heise, C: 6 articles (01/2002 - 03/2000)|
|5.||Ganly, I: 6 articles (03/2001 - 03/2000)|
|6.||Qian, Cheng: 5 articles (12/2007 - 04/2004)|
|7.||Kirn, David H: 5 articles (11/2007 - 02/2002)|
|8.||Reid, Tony R: 4 articles (08/2015 - 02/2003)|
|9.||Korn, W M: 4 articles (11/2009 - 10/2000)|
|10.||Portella, Giuseppe: 4 articles (10/2008 - 06/2002)|
03/01/2000 - "Using a pair of isogenic cell lines that differ only in their p53 status, we demonstrate here that although ONYX-015 can replicate in both p53 wild-type and mutant cells in vitro, the virus demonstrates significantly greater antitumor activity against mutant p53 tumors in vivo. "
02/01/2011 - "Oncolytic adenoviruses, such as ONYX-015, have been tested in clinical trials for currently untreatable tumors, but have yet to demonstrate adequate therapeutic efficacy. "
05/15/2000 - "The use of an Elb55k-deficient adenovirus, ONYX-015, to selectively target tumor cells containing a mutated p53 gene has produced promising results. "
02/01/2003 - "A Phase II trial of intralesional ONYX-015 was conducted in patients with hepatobiliary tumors to determine the safety and efficacy of such a treatment. "
08/01/2008 - "Data obtained from several clinical trials of the oncolytic adenovirus, ONYX-015, in patients with cancer have been described in detail. "
11/01/2006 - "ONYX-015 combined with MMC can produce significant cytotoxicity against T-24 cells and enhance therapeutic efficacy against bladder carcinoma."
02/01/2003 - "Therefore, we undertook a trial of the feasibility, tolerability, and efficacy of EUS injection of ONYX-015 into unresectable pancreatic carcinomas. "
11/01/2002 - "We performed a Phase II trial of an oncolytic replication-selective adenovirus (dl1520, also known as Onyx-015) administered by hepatic artery infusion in patients with gastrointestinal carcinoma metastatic to the liver (n = 27). "
01/01/2012 - "The recombinant virus AD55-Apoptin has more significant antitumor effect for hepatocelluar carcinoma cell lines (in vitro) than that of AD55 and even ONYX-015 but no or little impair on normal cell lines. "
01/15/2006 - "Ovarian carcinoma cell lines were transfected in vitro with dl922-947, adenovirus 5 wild-type (Ad5 WT), dl309, and dl1520 and monitored for S-phase induction, viral protein expression, replication, and overall survival. "
|3.||Prostatic Neoplasms (Prostate Cancer)
06/01/2001 - "A variety of provisionally replicating viruses, such as the attenuated adenovirus ONYX-015, the adenovirus CN706 that selectively replicates in prostate cancer cells, the double mutant herpes simplex virus G207, the human reovirus, and the Newcastle disease virus are currently in clinical trials. "
10/01/2010 - "The magnitude of the synergistic response was greatest for dl1520 whereas overall efficacy was greatest for dl922–947, and the latter was also more efficacious in vivo in prostate cancer models. "
10/01/2010 - "Here we report greatly improved antitumor efficacy for both attenuated (dl1520) and highly potent (dl922–947) oncolytic mutants in combination with the current standard of care for late-stage hormone-independent prostate cancers, mitoxantrone or docetaxel. "
|4.||Head and Neck Neoplasms (Head and Neck Cancer)
07/01/2006 - "The purpose of this review is to provide a prospective on the use of adenoviruses in head and neck cancer therapy by examining clinical trials of adenovirus-mediated p53 gene therapy and by reviewing the application of a promising oncolytic adenovirus, ONYX-015, in head and neck cancer."
04/15/2001 - "A particular example is the adenovirus ONYX-015, which has entered clinical trials in the context of head and neck cancer. "
01/15/2001 - "Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer."
03/01/2000 - "A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer."
01/01/1999 - "Onyx plans phase III trial of ONYX-015 for head & neck cancer."
|5.||Colorectal Neoplasms (Colorectal Cancer)
08/01/2005 - "Onyx-015 may benefit patients with refractory colorectal cancer and additional studies that include PET scans to assess clinical response are warranted."
04/15/2003 - "In this phase II study, intravenous CI-1042 was administered safely to patients with advanced colorectal cancer. "
04/15/2003 - "Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer."
11/01/2001 - "Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial."
02/01/2007 - "We administered an adenoviral vector, Onyx-015, into the hepatic artery of patients with metastatic colorectal cancer involving the liver. "
|8.||Tumor Suppressor Protein p14ARF (p14ARF)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)